Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study has been completed.
Study NCT01431521 Information provided by Merck Sharp & Dohme Corp.
First Received on September 7, 2011. Last Updated on October 16, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-alcoholic Fatty Liver Disease
Additional conditions recognized in this trial
More general conditions related to this trial
Digestive System Diseases
Interventions listed in this trial
MK-4074 200 mg
Placebo for MK-4074 100 mg
Pioglitazone hydrochloride 30 mg
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers